Circulating Matrix Metalloproteinase-3 and Metalloproteinase-9 and Tissue Doppler Measures of Diastolic Dysfunction to Risk Stratify Patients With Systolic Heart Failure

Thomas, 1998, Increased matrix metalloproteinases activity and selective upregulation in left ventricular myocardium from patients with end-stage dilated cardiomyopathy, Circulation, 97, 1708, 10.1161/01.CIR.97.17.1708 Spinale, 1999, Matrix metalloproteinase inhibition during the development of congestive heart failure, Circ Res, 85, 364, 10.1161/01.RES.85.4.364 Schwartzkopff, 2002, Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy, Eur J Heart Fail, 4, 439, 10.1016/S1388-9842(02)00092-2 Herpel, 2006, Interstitial fibrosis in the heart: differences in extracellular matrix proteins and matrix proteinases in end-stage dilated, ischaemic and valvular cardiomyopathy, Histopathology, 48, 736, 10.1111/j.1365-2559.2006.02398.x Kelly, 2007, Plasma matrix metalloproteinase-9 and left ventricular remodeling after acute myocardial infarction in man, Eur Heart J, 28, 10.1093/eurheartj/ehm003 Yamazaki, 2004, Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure, Eur J Heart Fail, 6, 41, 10.1016/j.ejheart.2003.05.002 George, 2005, Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure, Am Heart J, 150, 484, 10.1016/j.ahj.2004.11.016 Ohtsuka, 2007, Serum matrix metalloproteinase-3 as a novel marker for risk stratification of patients with nonischemic dilated cardiomyopathy, J Cardiac Fail, 13, 752, 10.1016/j.cardfail.2007.06.730 Vorovich, 2008, Comparison of matrix metalloproteinase-9 and brain natriuretic peptide as clinical biomarkers in chronic heart failure, Am Heart J, 155, 992, 10.1016/j.ahj.2008.01.007 Frantz, 2008, Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality, Eur J Heart Fail, 10, 388, 10.1016/j.ejheart.2008.02.015 Hillis, 2004, Noninvasive estimation of left ventricular filling pressure by E/e′ is a powerful predictor of survival after acute myocardial infarction, J Am Coll Cardiol, 43, 360, 10.1016/j.jacc.2003.07.044 Bruch, 2006, Risk stratification in chronic heart failure: independent and incremental prognostic value of echocardiography and brain natriuretic peptide and its N-terminal fragment, J Am Soc Echocardiogr, 19, 522, 10.1016/j.echo.2005.12.027 Dini, 2009, Value of tissue Doppler imaging for risk stratification of patients with chronic systolic heart failure with or without restrictive mitral flow, Eur J Echocardiogr, 10, 562, 10.1093/ejechocard/jep001 Lang, 2005, J Am Soc Echocardiogr, 18, 1440, 10.1016/j.echo.2005.10.005 Nagueh, 2009, Recommendations for the evaluation of left ventricular diastolic function by echocardiography, J Am Soc Echocardiogr, 22, 107, 10.1016/j.echo.2008.11.023 Ghio, 2000, Prognostic usefulness of the tricuspid annular plane systolic excursion in patients with congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy, Am J Cardiol, 85, 837, 10.1016/S0002-9149(99)00877-2 Yun, 2000, Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling, Cardiovasc Res, 46, 214, 10.1016/S0008-6363(00)00003-1 Spinale, 2000, A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure, Circulation, 102, 1944, 10.1161/01.CIR.102.16.1944 Peterson, 2000, Evolution of metalloproteinase and tissue inhibitor expression during heart failure progression in the infracted heart, Cardiovasc Res, 46, 307, 10.1016/S0008-6363(00)00029-8 Sundstrom, 2004, Relations of matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study, Circulation, 109, 2850, 10.1161/01.CIR.0000129318.79570.84 Polyakova, 2004, Matrix metalloproteinases and their tissue inhibitors in pressure overloaded human myocardium during heart failure progression, J Am Coll Cardiol, 44, 1609, 10.1016/j.jacc.2004.07.023 Tziakas, 2005, Comparison of levels of matrix metalloproteinase-2 and -3 in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy, Am J Cardiol, 96, 1449, 10.1016/j.amjcard.2005.06.096 Squire, 2004, Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohormonal parameters of left ventricular dysfunction, J Card Fail, 10, 328, 10.1016/j.cardfail.2003.11.003 Wagner, 2006, Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction, J Card Fail, 12, 66, 10.1016/j.cardfail.2005.08.002 Yan, 2008, Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure, Eur J Heart Fail, 10, 125, 10.1016/j.ejheart.2007.12.002 Ohtsuka, 2003, Serum levels of matrix metalloproteinases and tumor necrosis factor-alpha in patients with idiopathic dilated cardiomyopathy and effect of carvedilol on these levels, Am J Cardiol, 91, 1024, 10.1016/S0002-9149(03)00133-4